Bard boosts investment in percutaneous transluminal endomyocardial revascularisation (PTER) company:
This article was originally published in Clinica
Executive Summary
CR Bard has increased its investment in CorMedica, a US company developing systems for catheter-based percutaneous transluminal endomyocardial revascularisation (PTER). In March Bard secured exclusive worldwide distribution rights to eventual commercial products. Bard claims that PTER is a less-invasive technology that TMR and that CorMedica has a proprietary catheter tracking and navigation system.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.